10-Q: CalciMedica Reports Q3 2024 Results, Highlights Progress in Clinical Trials

CalciMedica's Q3 2024 report details financial results and provides updates on clinical trials, including the ongoing Phase 2 trial for Auxora in acute kidney injury.

Summary

• CalciMedica, a clinical-stage biopharmaceutical company, released its financial results for the third quarter of 2024, showing a net loss of $5.6 million.
• The company's operating expenses totaled $5.7 million, with research and development accounting for $3.5 million and general and administrative expenses at $2.2 million.
• For the nine months ended September 30, 2024, the net loss was $9.4 million, with total operating expenses of $18 million.
• The company had cash, cash equivalents, and short-term investments of $14.6 million as of September 30, 2024.
• CalciMedica completed a private placement in January and February 2024, raising net proceeds of approximately $19 million.
• A follow-on public offering in November 2024 raised gross proceeds of $10.2 million.
• The company is focused on developing therapeutics for inflammatory and immunologic diseases, with its lead product candidate, Auxora, in Phase 2 clinical trials.
• The company is conducting a Phase 2 trial for Auxora in acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF), with results expected in 2025.
• The company also plans to submit an IND to the FDA for CM6336 in 2025 for the treatment of chronic pancreatitis and/or rheumatoid arthritis.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making progress in its clinical trials and has secured additional funding, it continues to incur significant losses and faces substantial risks. The sentiment is neutral to slightly negative due to the ongoing losses and the inherent risks of drug development.

Positives

• The company successfully raised additional capital through a private placement and a follow-on public offering.
• The company is actively progressing its lead product candidate, Auxora, through Phase 2 clinical trials.
• The company has a pipeline of product candidates and plans to submit an IND for CM6336 in 2025.
• The company has received Fast Track designation for Auxora for the treatment of AP in the US and orphan drug designation in the EU.

Negatives

• The company continues to incur net losses, with a $5.6 million loss in Q3 2024 and a $9.4 million loss for the nine months ended September 30, 2024.
• The company has a limited operating history and has not generated any revenue from product sales.
• The company is dependent on third parties for manufacturing and clinical trials.
• The company's future success is highly dependent on the success of Auxora.

Risks

• The company's proprietary CRAC channel inhibition science is based on novel technologies that are unproven and may not result in approvable or marketable products.
• The company will need to obtain substantial additional funding to complete the development and any commercialization of its product candidates.
• Clinical development is a lengthy, expensive, and uncertain process, and results of preclinical studies and early clinical trials are not always predictive of future results.
• The company relies on third parties to conduct and perform most of its research, preclinical studies, and clinical trials.
• The company contracts with third parties for the manufacturing and supply of certain goods and services for its product candidates, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.
• Any approved product candidates may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors, and others in the medical community necessary for commercial success.
• The company may not be able to successfully commercialize its product candidates due to unfavorable pricing regulations or third-party coverage and reimbursement policies.
• The company is highly dependent on its key personnel, and if it is not successful in attracting and retaining highly qualified personnel, it may not be able to continue to successfully develop or commercialize its product candidates or otherwise implement its business plan.
• If the company is unable to obtain and maintain sufficient intellectual property protection for Auxora, any future product candidates, and other proprietary technologies it develops, or if the scope of the intellectual property protection obtained is not sufficiently broad, its competitors could develop and commercialize products similar or identical to ours, and its ability to successfully commercialize Auxora, any future product candidates, and other proprietary technologies if approved, may be adversely affected.

Future Outlook

The company expects its cash, cash equivalents, and short-term investments, including proceeds from the 2024 Follow-On, will be sufficient to fund operations through certain clinical milestones into the first half of 2026. The company plans to submit an IND to the FDA for CM6336 in 2025 and to pursue developing the drug for treatment of chronic pancreatitis and/or rheumatoid arthritis.

Management Comments

• Management believes its cash, cash equivalents and short-term investments will be sufficient to fund its operations for the period of at least one year following the issuance of these financial statements.
• Management expects to incur significant expenses and increasing operating losses for the foreseeable future as the Company initiates and continues the preclinical and clinical development of its product candidates and adds personnel necessary to operate as a company with an advanced clinical pipeline of product candidates.

Industry Context

The company operates in the competitive biopharmaceutical industry, focusing on novel CRAC channel inhibitors for inflammatory and immunologic diseases. The company's approach is unique, as there are no approved therapies using similar technology. The company is competing with other companies developing therapies for acute critical illnesses.

Comparison to Industry Standards

• CalciMedica's financial results are typical for a clinical-stage biopharmaceutical company, with significant operating losses and reliance on external funding.
• The company's cash burn rate is consistent with other companies in the sector, given the high costs of clinical trials and research and development.
• The company's focus on novel CRAC channel inhibitors is a differentiating factor, but also carries higher risk due to the unproven nature of the technology.
• The company's reliance on third-party manufacturers and CROs is common in the industry, but also introduces risks related to supply chain and trial execution.
• The company's clinical trial progress is comparable to other companies in the sector, with Phase 2 trials underway for its lead product candidate, Auxora.
• The company's plans to submit an IND for CM6336 in 2025 is consistent with the development timelines of other companies in the sector.

Related Party Transactions

• The company recorded expense of $57,000 and $94,000 during the three months ended September 30, 2024 and 2023, respectively and $243,000 and $440,000 during the nine months ended September 30, 2024 and 2023, respectively, for consulting fees paid to a firm affiliated with the company's interim chief financial officer.
• In May 2024, the Company granted a warrant to purchase 10,000 shares of common stock to a consulting firm affiliated with the Company's interim chief financial officer.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises and the potential for loss of investment if the company is unable to successfully develop and commercialize its product candidates.
• Employees are subject to the risks associated with a clinical-stage company, including potential job insecurity and the possibility of stock options not realizing their full value.
• Patients may benefit from the development of new therapies for inflammatory and immunologic diseases, but also face the risks associated with clinical trials and the uncertainty of regulatory approval.
• Suppliers and contract manufacturers are subject to the risks associated with the company's financial stability and the success of its product candidates.
• Creditors face the risk of non-payment if the company is unable to secure additional funding or generate revenue.

Next Steps

• Continue enrollment in the Phase 2 KOURAGE trial for Auxora in AKI with AHRF.
• Submit an IND to the FDA for CM6336 in 2025.
• Discuss the full results of the CARPO trial with the FDA in an end-of-Phase 2 meeting.
• Initiate a Phase 3 program in AP in 2025.
• Continue data collection for the CRSPA trial in pediatric patients with AIPT.

Key Dates

Keywords

CalciMedica, Auxora, CRAC channel inhibitors, clinical trials, biopharmaceutical, acute kidney injury, acute hypoxemic respiratory failure, CM6336, private placement, public offering, net loss, research and development, regulatory approval